What is Appia Bio?
Founded in 2020 and headquartered in Los Angeles, CA, Appia Bio is dedicated to the discovery and development of engineered allogeneic cell therapies. The company leverages a scalable technology platform designed to broaden patient access to innovative treatments across a wide spectrum of indications. Its focus on early-stage biotechnology positions it at the forefront of therapeutic innovation.
How much funding has Appia Bio raised?
Appia Bio has raised a total of $52M across 1 funding round:
Series A
$52M
Series A (2021): $52M with participation from 8VC, Freeflow Ventures, Sherpa Healthcare Partners, and Two Sigma Ventures
Key Investors in Appia Bio
8VC
8VC is a leading technology investment firm, investing in visionary teams and backing industry-transforming companies. The partners have a proven track-record as founders, engineers, and operators of successful companies including Palantir, Addepar, Affinity and OpenGov, amongst others. 8VC was founded in 2012 and manages $3.6 billion in committed capital. The firm invests primarily in smart enterprise platforms across industries including financial services, healthcare, logistics, Bio-IT, and others.
Freeflow Ventures
Freeflow Ventures is an investment firm that provides capital for companies. Further details on their investment focus are not specified in the provided data.
Two Sigma Ventures
Two Sigma Ventures is an early-stage venture capital firm that invests in transformative companies leveraging information growth and computing power. The firm focuses on technology that enhances human potential, breakthrough therapies, artificial intelligence, and online safety for children. They support startups across various industries, from healthcare to consumer hardware, and provide expertise in data science and advanced engineering. With a commitment to challenging convention and fostering innovation, Two Sigma Ventures partners with visionary founders to drive data-driven transformation.
What's next for Appia Bio?
The recent major strategic investment signals a pivotal growth phase for Appia Bio, likely enabling the company to accelerate its research and development pipelines, expand its clinical trial initiatives, and further scale its proprietary technology platform. This capital infusion is expected to bolster its efforts in bringing novel cell therapies to market, reinforcing its position as a key player in the biotechnology sector.
See full Appia Bio company page
